Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO)
Oct 17, 2025
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Gordon et al.
Filter by
Balstilimab (PD-1 Antagonist), Zalifrelimab (CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO)
Oct 18, 2025
Efficacy and safety of balstilimab with or without zalfrelimab in recurrent cervical cancer: Results from the global phase 2 RaPiDs trial (GOG-3028)
O’Malley, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO)
Oct 17, 2025
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Gordon et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society of Medical Oncology (ESMO)
Jul 4, 2025
Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite stable colorectal cancer and no active liver metastases
Schlechter, et al.
Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society of Clinical Oncology
May 30
- Jun 3, 2025
Monitoring botensilimab- and balstilimab-induced T cell dynamics in refractory mismatch repair proficient metastatic colorectal cancer
Rasschaert et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 25
- Apr 30, 2025
Results from a phase 1 study of botensilimab and balstilimab in treatment refractory hepatocellular carcinoma
El-Khoueiry, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 25
- Apr 30, 2025
Neoadjuvant botensilimab plus balstilimab in MMR proficient and deficient early-stage cancers: first results of the pan-cancer NEOASIS study
Chalabi et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR) IO
Feb 23
- Feb 26, 2025
First-line Botensilimab and Balstilimab OPtimization in Microsatellite Stable COlorectal Cancer
without liver, bone, or brain metastasis
DeVito et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR) IO
Feb 24, 2025
Biomarker Analysis From a Phase II Study of AgenT-797 (invariant natural killer T cells) with Botensilimab (Fc-enhanced CTLA-4 inhibitor) and Balstilimab (anti-PD-1) in PD-1 Refractory Gastroesophageal Cancer
Cytryn et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Association for Cancer Research (AACR) IO
Feb 24, 2025
Biomarker analysis from phase 2 study of agenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced
CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC)
Cytryn et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Journal of Clinical Oncology
Jan 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
Preliminary Results From a Randomized, Open-Label, Phase 2 Study of Botensilimab With or Without Balstilimab in Refractory Microsatellite Stable Metastatic Colorectal Cancer With No Liver Metastases
Fakih, et al.
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
A Phase I Trial of Folinic Acid, Fluorouracil, Oxaliplatin, Bevacizumab, Botensilimab, Balstilimab (FOLFOX-3B) in Microsatellite Stable Metastatic Colorectal Cancer
Fakih, et al.